RxDoctor Payments Data

Hyder Jamal, MD

Gastroenterology · Yorba Linda, CANPI 1740280932

Payments from drug & device makers

$191,026in general payments, 2019–2025

Across 741 payments — averaging $257.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ironwood Pharmaceuticals, Inc$99K
  • Gilead$68K
  • AbbVie$8K
  • Adare Pharmaceuticals, Inc.$5K
  • Mallinckrodt Hospital Products Inc.$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • plus $8K from 34 others

What the payments were for

  • Consulting fees$10,01012%
  • Speaking & faculty fees$56,41068%
  • Travel & lodging$9751%
  • Food & beverage$15,11718%
  • Education$1680%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$191,026 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$129,242
Medicare patients
524
Services billed
862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide99$160,760
RezdiffraResmetirom11$42,534
XifaxanRifaximin15$42,439
CreonLipase/Protease/Amylase18$17,766
LinzessLinaclotide30$16,807
Ursodiol70$14,164
Mesalamine31$8,692
Mesalamine ErMesalamine14$6,332
Dexlansoprazole DrDexlansoprazole11$5,849
Pantoprazole Sodium570$5,791
Tenofovir Disoproxil Fumarate19$4,099
Sucralfate58$2,990
CholestyramineCholestyramine (With Sugar)32$2,755
Entecavir15$2,563
Omeprazole120$1,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$68,024$160,76099 claims
Madrigal PharmaceuticalsRezdiffra$213$42,53411 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,874$42,43915 claims
AbbVieCreon, Linzess$8,119$34,57348 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Yorba Linda

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →